Delivering CAR-T close to home is a question of organization more than size. Here is what a program needs across space, product handling, collection, critical care access and monitoring. We also highlight which pieces a partner can reasonably carry for you.
No single model fits every practice. The building blocks are the same everywhere: clinical space, product handling, apheresis, critical care access and post-infusion monitoring. Which you build and which you contract depends on your resources and constraints. Standard Operating Procedures should be developed to ensure adherence to quality management and regulatory compliance.
Identifying space for infusion and for post-infusion monitoring is a distinct planning step, not an assumption. A hospital setting isn’t needed, but having a close working relationship with a collaborating hospital for adverse event management is wise. Whatever space you use, think through how you may manage any potential side effects.
The product arrives in a vapor-phase nitrogen dry shipper. The first checks are to ensure packaging integrity, transit temperature, bag integrity, labeling, number of bags and expiry. Chain of identity verified again against the identifiers which were recorded at collection. If storing, on-site storage needs temperature monitoring with 24-hour alarms. Some centers choose to deliver just-in time, because thawed cells stay stable for only about 30 to 90 minutes. Receiver and the infusion team work to one schedule to ensure correct delivery.
Leukapheresis is commonly performed in an outpatient community setting. The apheresis order is best placed in the same system as the CAR-T prescription so washout periods for G-CSF, cytotoxics and steroids can be verified. Chain of custody is critical including double-checking the bag against patient identifiers and the Donation Identification Number. If building a unit is not realistic, apheresis is among the services most readily contracted to a qualified provider.
Side effects from CAR-T therapies can be serious, but are manageable, and they need fast escalation. A defined pathway matters more than owning an emergency department or ICU. Work through ambulance, emergency department, ICU, neurology and cardiology together, and agree admission criteria before the first patient rather than during. Ensure you have the necessary medications to manage side effects on hand per patient.
Patients must stay near the treating facility up to two weeks. Daily assessment for the first seven days and weekly review for at least a month, through in-person visits or remote monitoring. Work with your product manufacturer to best understand monitoring timing. A critical importance for smaller practices is to plan after-hours, weekend and holiday monitoring. For events outside of business hours, a dedicated line that bypasses emergency services is one option to consider.
These are the core functions a CAR-T program needs to cover. Depending on your size, one person may take on several of these.
A medical director, physician or advanced practice nurse holding clinical accountability. Cellular therapy training or experience in BMT may help with speed of adoption.
Guides each patient from referral through follow-up and keeps physicians, apheresis, pharmacy, the manufacturer, reimbursement and your partner hospital on one timeline.
Owns receipt, chain of identity and custody, storage or thaw scheduling, and immediate tocilizumab availability on infusion day.
A designated role covering SOPs, training and competency records, outcome reporting and the written agreements you hold with collection, laboratory and hospital partners.
Major workstreams progress in parallel as centers advance through a common readiness and activation journey
Align on goals, scope, stakeholders, and requirements
Evaluate capabilities, identify gaps, and plan for remediation
Put in place agreements, technology, logistics, and operational infrastructure
Develop workflows, SOPs, safety processes, and interdisciplinary coordination
Train teams, validate competencies, and confirm end-to-end readiness
Authorize center to treat patients and provide ongoing support and quality oversight
This model shows how common workstreams overlap and progress in parallel across the onboarding journey. The duration of each stage and workstream will vary based on therapy, manufacturer, center readiness, existing infrastructure, regulatory environment, and local processes.
Primary focus
Continued as needed
A treatment-ready center delivering safe, high-quality cell therapy to more patients
Case Study
Practice Profile: Billings Clinic Cancer Center
ACCC's profile of how a rural health system stood up a CAR-T program, covering implementation, staff education and communication with referring providers.
Case Study
Targeted Oncology Article
"Expanding CAR T-Cell Therapy in Community Oncology" Virginia Cancer Specialists built a community CAR-T program, covering leadership, care pathways, team, hospital partners, payers, and early cases
We’re here to help. Reach out today to connect with experts that can guide you.
